本研究旨在系统评价和批判性评估Brentuximab vedotin（BV）治疗霍奇金淋巴瘤（HL）患者的成本效益研究。检索PubMed、Scopus、Web of Science核心集合和Embase数据库，截至2022年7月3日。我们纳入了发表的关于BV治疗HL患者的完整经济评估研究。使用卫生经济学研究质量（QHES）核对表评估研究的方法学质量。同时，我们使用定性综合分析研究结果。我们将增量成本效益比（ICERs）转换为2022年美元的价值。满足研究纳入标准的经济评估共有8篇。比较BV加多柔比星、长春碱和达卡巴嗪（BV+AVD）一线治疗与多柔比星、博来霉素、长春碱和达卡巴嗪（ABVD）的三项研究结果显示，BV在晚期（III或IV期）HL患者中作为一线治疗很可能不具备成本效益。四项研究调查了BV在自体干细胞移植（ASCT）后复发或难治（R/R）HL患者中的成本效益。在接受审查的研究中，BV不具备成本效益，并且调整后的ICER在每质量调整生命年（QALY）范围为65,382美元至374,896美元。影响成本效益的关键因素是药物成本、BV的危险比和效用。现有的经济评估显示，根据HL或R/R HL患者特定ICER阈值，将BV用作一线治疗或巩固治疗是不具备成本效益的。为决策使用这种孤儿药物，我们应该考虑其他因素，如存在替代治疗选择、临床效益和疾病负担。© 2023. 作者（们），独家许可Springer-Verlag GmbH Germany发行部，属于Springer Nature。

This study aimed to systematically review and critically appraise cost-effectiveness studies on Brentuximab vedotin (BV) in patients with Hodgkin lymphoma (HL).The PubMed, Scopus, Web of Science core collection, and Embase databases were searched until July 3, 2022. We included published full economic evaluation studies on BV for treating patients with HL. The methodological quality of the studies was assessed using the Quality of Health Economic Studies (QHES) checklist. Meanwhile, we used qualitative synthesis to analyze the findings. We converted the incremental cost-effectiveness ratios (ICERs) to the value of the US dollar in 2022.Eight economic evaluations met the study's inclusion criteria. The results of three studies that compared BV plus doxorubicin, vinblastine, and dacarbazine (BV + AVD) front-line therapy with doxorubicin, bleomycin, vincristine, and dacarbazine (ABVD) showed that BV is unlikely to be cost-effective as a front-line treatment in patients advanced stage (III or IV) HL. Four studies investigated the cost-effectiveness of BV in patients with relapsed or refractory (R/R) HL after autologous stem cell transplantation (ASCT). BV was not cost-effective in the reviewed studies at accepted thresholds. In addition, the adjusted ICERs ranged from $65,382 to $374,896 per quality-adjusted life-year (QALY). The key drivers of cost-effectiveness were medication costs, hazard ratio for BV, and utilities.Available economic evaluations show that using BV as front-line treatment or consolidation therapy is not cost-effective based on specific ICER thresholds for patients with HL or R/R HL. To decide on this orphan drug, we should consider other factors such as existence of alternative treatment options, clinical benefits, and disease burden.© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.